Literature DB >> 23003320

A comparison of human immunodeficiency virus, hepatitis C virus, hepatitis B virus, and human T-lymphotropic virus marker rates for directed versus volunteer blood donations to the American Red Cross during 2005 to 2010.

Kerri A Dorsey1, Erin D Moritz, Whitney R Steele, Anne F Eder, Susan L Stramer.   

Abstract

BACKGROUND: At most US blood centers, patients may still opt to choose specific donors to give blood for their anticipated transfusion needs. However, there is little evidence of improved safety with directed donation when compared to volunteer donation. STUDY DESIGN AND METHODS: The percentage of directed donations made to the American Red Cross (ARC) from 1995 to 2010 was determined. Infectious disease marker rates for human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), and human T-lymphotropic virus (HTLV) were calculated for volunteer and directed donations made from 2005 to 2010. Odds ratios (ORs) were calculated to compare marker-positive rates of directed donations to volunteer donations.
RESULTS: The percentage of donations from directed donors declined from 1.6% in 1995 to 0.12% in 2010. From 2005 to 2010, the ARC collected 38,894,782 volunteer and 69,869 directed donations. Rates of HIV, HCV, HBV, and HTLV for volunteer donations were 2.9, 32.2, 12.4, and 2.5 per 100,000 donations, respectively; for directed, the rates were 7.2, 93.0, 40.1, and 18.6 per 100,000. After demographics and first-time or repeat status were adjusted for, corresponding ORs of viral marker positivity in directed versus volunteer donations were not significant for HIV, HBV, or HTLV and significant for HCV (OR, 0.7; 95% confidence interval, 0.50-0.90).
CONCLUSIONS: Directed donations have declined by 92% at the ARC since 1995, but have higher viral marker rates than volunteer donations. The difference can be explained in part by the effects of first-time or repeat status of the donors. Patients considering directed donation should be appropriately counseled about the potential risks.
© 2012 American Association of Blood Banks.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23003320     DOI: 10.1111/j.1537-2995.2012.03904.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  12 in total

1.  Free blood donation mobile applications.

Authors:  Sofia Ouhbi; José Luis Fernández-Alemán; Ambrosio Toval; Ali Idri; José Rivera Pozo
Journal:  J Med Syst       Date:  2015-03-03       Impact factor: 4.460

2.  Detection of Nicotine and Nicotine Metabolites in Units of Banked Blood.

Authors:  Joesph R Wiencek; Eric A Gehrie; Amaris M Keiser; Penny C Szklarski; Kamisha L Johnson-Davis; Garrett S Booth
Journal:  Am J Clin Pathol       Date:  2019-04-02       Impact factor: 2.493

Review 3.  THE POWER OF POOP: FECAL MICROBIOTA TRANSPLANTATION FOR CLOSTRIDIUM DIFFICILE INFECTION.

Authors:  Michael B Edmond
Journal:  Trans Am Clin Climatol Assoc       Date:  2016

4.  Recent and occult hepatitis B virus infections among blood donors in the United States.

Authors:  Sumathi Ramachandran; Jamel A Groves; Guo-Liang Xia; Paula Saá; Edward P Notari; Jan Drobeniuc; Amanda Poe; Natasha Khudyakov; Sarah F Schillie; Trudy V Murphy; Saleem Kamili; Chong-Gee Teo; Roger Y Dodd; Yury E Khudyakov; Susan L Stramer
Journal:  Transfusion       Date:  2018-11-30       Impact factor: 3.157

5.  Transfusion-associated hepatitis before the screening of blood for hepatitis risk factors.

Authors:  Ronald E Engle; Jens Bukh; Harvey J Alter; Suzanne U Emerson; Joni L Trenbeath; Hanh T Nguyen; Alicia Brockington; Tanaji Mitra; Robert H Purcell
Journal:  Transfusion       Date:  2014-05-05       Impact factor: 3.157

Review 6.  Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook.

Authors:  Colleen R Kelly; Stacy Kahn; Purna Kashyap; Loren Laine; David Rubin; Ashish Atreja; Thomas Moore; Gary Wu
Journal:  Gastroenterology       Date:  2015-05-15       Impact factor: 22.682

Review 7.  Clostridium difficile Infection and Fecal Microbiota Transplant.

Authors:  Alyssa Liubakka; Byron P Vaughn
Journal:  AACN Adv Crit Care       Date:  2016-07

8.  Costs per Diagnosis of Acute HIV Infection in Community-based Screening Strategies: A Comparative Analysis of Four Screening Algorithms.

Authors:  Martin Hoenigl; Joshua Graff-Zivin; Susan J Little
Journal:  Clin Infect Dis       Date:  2015-10-27       Impact factor: 9.079

9.  Fecal microbiota transplant: benefits and risks.

Authors:  Ana A Weil; Elizabeth L Hohmann
Journal:  Open Forum Infect Dis       Date:  2015-02-04       Impact factor: 3.835

Review 10.  Nutritional Keys for Intestinal Barrier Modulation.

Authors:  Stefania De Santis; Elisabetta Cavalcanti; Mauro Mastronardi; Emilio Jirillo; Marcello Chieppa
Journal:  Front Immunol       Date:  2015-12-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.